1. Home
  2. HURN vs PHVS Comparison

HURN vs PHVS Comparison

Compare HURN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$157.78

Market Cap

2.5B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$32.02

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
PHVS
Founded
2002
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
HURN
PHVS
Price
$157.78
$32.02
Analyst Decision
Strong Buy
Buy
Analyst Count
5
11
Target Price
★ $204.40
$41.82
AVG Volume (30 Days)
183.9K
★ 1.0M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.34
N/A
Revenue
★ $1,699,143,000.00
N/A
Revenue This Year
$11.80
N/A
Revenue Next Year
$8.23
N/A
P/E Ratio
$117.66
★ N/A
Revenue Growth
★ 11.65
N/A
52 Week Low
$84.88
$20.65
52 Week High
$186.78
$43.25

Technical Indicators

Market Signals
Indicator
HURN
PHVS
Relative Strength Index (RSI) 56.56 33.49
Support Level $143.69 $25.17
Resistance Level $165.37 $36.80
Average True Range (ATR) 4.98 2.22
MACD -0.28 -0.66
Stochastic Oscillator 79.98 3.57

Price Performance

Historical Comparison
HURN
PHVS

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: